In this review a number of recently published key developments and publications in the field of allergen immunotherapy (AIT) will be discussed. Large AIT studies with state-of-the-art protocols, evaluations, and reporting for allergic rhinitis (AR) and allergic asthma have been performed, which increase considerably the efficacy of specific AIT products and develop the field into the future of evidence-based treatment. 1 Both subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT) have been established as viable and safe procedures if administered with the correct products. 2 The international consensus consortium on AIT has further encouraged researchers in the field to contribute to the generation of hypoallergenic recombinant allergen derivatives and immunogenic peptides, developing new adjuvants and stimulators of the innate immune response, fusion of allergens with immune modifiers and peptide carrier proteins for efficient vaccination, and new routes of vaccine administration. 3 This review highlights new studies performed on the efficacy and safety of SCIT and SLIT to allow for best practices in AIT treatment and current developments in mechanisms of immune tolerance to allergens using AIT as the best human in vivo model to study immune regulation.
EVIDENCE IN AIT: META-ANALYSES AND GUIDELINES
Universal standardization of allergen extracts is a prerequisite to develop efficient tools for the diagnosis and therapy of atopic disease. Allergen extracts are being standardized by using established methods to control their potency, composition, and stability of the major allergen; however, there is no universally accepted methodology that enables the comparison of products of different companies and spans all AIT vaccines. 3 In addition, state-of-the art studies with AIT products should provide evidence for efficacy and tolerability. European directives classified allergen products as medicinal products, providing specifications for these products in both diagnostics and AIT. Under these regulations, allergen products require a market authorization similar to medicinal drugs, which includes dose finding and confirmation of efficacy and tolerability in phase III studies. Because allergen products are meant to modulate immune tolerance in the patient, such prerequisites seem more than justified to ensure efficacious treatment.
Although a large number of national and international guidelines for AIT have been developed, 2 they do not base their recommendations on established doses per product but rather on use of meta-analyses of registered and nonregistered products, for which dose-finding studies might not even be available. As a consequence of the heterogeneity of meta-analyses, these guidelines limit their conclusions to general statements on AIT, mostly based on the application route; they can by no means be of support to select an efficacious product for a specific patient. Obviously, claims from meta-analyses or from specific AIT products cannot be used for any other product; there is no ''class effect'' caused by the heterogeneity in composition and dosing of individual products. 4 This becomes specifically obvious for AIT in children, claims on asthma prevention, and so on, but also excludes claims on mixtures unless optimal dosing is used per allergen in the mixture. However, this meets obvious limitations regarding safety. A recent World Allergy Organization statement indicates the need for product-specific evidence-based AIT. 5 In the past, we were used to honoring meta-analyses for their high scientific status; however, there is some criticism on flaws in technique and also wrong conclusions from meta-analyses. [6] [7] [8] Meta-analyses should provide the highest level of evidence for the efficacy of a medical treatment or intervention. In recent years, there has been an overflow of meta-analyses on AIT with contrasting results that might generate confusion among physicians. 8 Flaws can result from incorrect selection of trials, inappropriate use of evaluation parameters for the analysis, bias toward unpublished studies, unsuitable analyses, and overinterpretation of the results. The most obvious error results from the selection of different products into one meta-analysis, which necessarily results in heterogeneity. It is clear that a meta-analysis of several small studies with various products does not predict the result of a state-of-the-art large study with a dose-optimized standardized product.
The gold standard for AIT is a product for which a dose-ranging study has been performed and larger phase III studies are available for adults and children over at least 1 year of treatment and, optimally, a study in adults over 3 years and 2 years of follow-up for claims on long-term efficacy and disease modification. 5, 9 One such study tested grass pollen products in patients with moderate-to-severe AR undergoing grass pollen SLIT and SCIT for 2 years with a 3-year follow-up and found no significant improvement of nasal response over placebo control at the third year. However, grass pollen-specific IgE levels were decreased after 2 and 3 years in patients undergoing SCIT. 10 
RECENT ADVANCES IN AIT FOR ALLERGIC RHINOCONJUNCTIVITIS AND ASTHMA
House dust mites (HDMs) are major perennial allergen sources and a significant cause of AR and allergic asthma; a recent overview showed that 65 to 130 million persons worldwide might have HDM allergy, with up to 50% of asthmatic patients being sensitized. 11 HDM sensitizations are more frequently associated with both rhinitis and asthma than any other frequent allergen. Still, HDM allergies remain undiagnosed and undertreated. As a consequence, the need for treatment of HDM-induced asthma and AR is high; thus far, however, there has been a deficit in adequately studied AIT products for patients with HDM allergy. Furthermore, international guidelines restricted AIT application in patients with uncontrolled asthma. 4 During the past 2 years, dose-finding studies in exposure chambers 12, 13 and classical state-of-the-art field trials [14] [15] [16] [17] have provided strong evidence for the efficacy, tolerability, and safety of HDM sublingual immunotherapy tablets in both adults and adolescents (>12 years) with AR (see Table E1 in this article's Online Repository at www.jacionline.org). [12] [13] [14] [15] [16] [17] Moreover, for the first time, a large multicenter randomized controlled trial (RCT) has studied the effect of HDM sublingual tablets in adults (n 5 834) with HDM allergy-related asthma that was not well controlled by inhaled corticosteroids or combination treatment. The study showed a significantly reduced risk for moderate or severe asthma exacerbations, as defined by American Thoracic Society-European Respiratory Society criteria during a 6-month period of inhaled corticosteroid reduction. Treatment-related adverse events were common but were primarily mild-to-moderate local reactions. Further studies are needed to evaluate the long-term efficacy and safety of HDM AIT in asthmatic patients. provocation test after 12 months of treatment with HDM allergoid SCIT in the 3 higher-dose groups. A post hoc analysis of the combined symptom and medication scores in a subgroup of patients with a higher score at the start of the study showed a significant treatment effect in the 2 higher dosages for the last 8 weeks of study, potentially translating the efficacy observed in the nasal challenge to clinics. However, because of a higher incidence of adverse events in the highest dose group, the study favored intermediate doses for further clinical use. This study demonstrates that both efficacy and safety have to be taken into account when developing optimal AIT drugs.
It has been suggested previously that AIT might prevent the onset of new sensitizations and the manifestation of asthma in patients with AR. A prospective, randomized, double-blind, placebo-controlled proof-of-concept study involved 111 infants (age, 5-9 months) at high hereditary risk to atopy (> _2 first-degree relatives with allergic disease) with negative skin prick test responses to common food allergens and aeroallergens at randomization. The study revealed that twice-daily administration for 12 months of high-dose HDM extract oral immunotherapy (OIT) solution was associated with a significant reduction in sensitization to any common allergen compared with placebo; however, no significant preventive effect was observed on HDM sensitization or allergy-related symptoms. Thus it remains unclear whether early intervention in high-risk children is a valuable option. 20 For the first time, however, evidence for a reduction in the development of asthma in patients with AR diagnosed according to the International Statistical Classification of Diseases, 10th Edition, caused by AIT has been provided in a ''real-life,'' large, retrospective, cohort study by using routine health care data from German National Health Insurance beneficiaries. 21 The cohort consisted of 118,754 patients with allergic rhinoconjunctivitis but without asthma at inclusion who had not received AIT before. The study revealed a significantly reduced risk of incident asthma for 5 years in patients exposed to AIT compared with those receiving no AIT (risk reduction by 40%). Sensitivity analyses suggested significant preventive effects of SCIT with native (nonallergoid) allergens.
ADVANCES IN AIT ROUTES AND PREPARATIONS
Conventional SCIT is associated with some disadvantages, including the need for frequent injections over a minimum of 3 years, the need for visits to the doctor's office, and the risk for adverse events, including life-threatening anaphylaxis in few cases. SLIT has emerged as an alternative user-friendly approach, allowing self-administration at home and at the same time reducing the risk of severe systemic reactions. However, SLIT requires daily intake for 3 years, challenging patient adherence to the treatment. As a consequence, novel AIT approaches are constantly in development (Table I) . [22] [23] [24] [25] [26] [27] [28] These approaches aim to improve safety and patient convenience while preserving or even improving efficacy. 29 Strategies include both alternative routes of administration (including intradermal, epicutaneous, intralymphatic, oral, or nasal administration) and alterations of the allergens (including allergoids, purified recombinant allergens, recombinant hypoallergenic allergens, and allergen peptides). 29 Finally, the safety and efficacy of AIT can be improved when combined with other innovative treatments (eg, mAbs to IgE or T H 2 cytokines). Intradermal injections and epicutaneous applications with allergen patches have been proposed, but results have not been convincing thus far. Repeated intradermal administrations of very low doses of grass pollen allergen extract have previously been associated with suppressed allergen skin late-phase responses 30 ; however, a recent RCT with preseasonal intradermal grass AIT 22 showed an increase in responsiveness and did not show beneficial effects on allergic symptoms. The efficacy of epicutaneous AIT for treatment of grass polleninduced AR was supported previously by 2 RCTs, 31, 32 but a recent trial performed by the same group 23 confirmed significant symptom improvement compared with placebo in the year of treatment but not the year after discontinuation. Hence a single course of preseasonal epicutaneous AIT was not associated with long-term efficacy.
Intralymphatic AIT involves a small number of injections of low doses of allergen directly into a lymph node. Efficacy and safety have been suggested for pollen-induced 33 and cat-induced 34 AR. An additional small cohort of patients with grass-or birch pollen-induced AR 24 also showed an improved global evaluation of seasonal symptoms. In conclusion, further assessment in well-designed, large-scale RCTs is needed before intralymphatic AIT is ready for clinical use. 35 Investigations of allergen content and characterization of drug products used for clinical trials for OIT have been limited thus far. One study showed that peanut flour contains the major peanut allergens Ara h 1 and Ara h 2 in complete form and thus can be a viable product for peanut OIT with its low bacterial content and long shelf life. 36 In recent years, 2 types of T-cell epitope-based allergen peptides have been developed and assessed in RCTs: short T-cell epitope peptides (also named synthetic peptide immunoregulatory epitopes) and longer contiguous overlapping peptides (COPs). 37 Previous trials with cat, 38 HDM, 39 and grass 40 synthetic peptide immunoregulatory epitope immunotherapy were encouraging. A more recent dose-finding phase II trial evaluating the effect of grass peptide AIT showed significant improvement of rhinoconjunctivitis symptoms to grass allergen challenge with one of 3 tested dosing schemes. 25 However, the results of the phase III trial with cat peptide AIT and the phase IIb trial with HDM peptide AIT did not achieve clinical end points. 41, 42 In the COP-based approach all possible T-cell epitopes of the target allergen are included in a small set of long synthetic peptides that are unable to bind IgE. Good clinical tolerability of Bet v 1-derived COP-based SCIT was shown in a previous phase I/IIa clinical trial in patients with birch pollen-induced AR, and clinical efficacy compared with placebo was demonstrated more recently in a phase IIb trial with the lower of 2 dosing schemes. 26 In addition, a hypoallergenic B-cell epitope-based peptide vaccine has been developed for grass pollen allergy. The vaccine lacks IgE reactivity and has maximally reduced allergen-specific T-cell epitopes, aiming to avoid IgE-mediated early-phase and T cell-mediated late-phase adverse events. 43 Both the safety and efficacy of this novel vaccine have been investigated in a phase II trial 27 ; a single course of 3 monthly subcutaneous injections was effective in reducing allergen-induced symptoms versus baseline in the setting of an exposure chamber trial. No systemic immediate-type events and only a few grade 1 systemic late-phase reactions occurred. Further trials are needed to establish the potential of this novel B-cell epitope-based vaccine. Finally, a small single-center RCT evaluated the combined approach of suboptimal grass SCIT with monoclonal anti-IL-4 treatment. Although anti-IL-4 treatment was effective in modulating T H 2 memory, the study did not reveal additional benefit of combined treatment with anti-IL-4 over treatment with suboptimal grass SCIT alone on the allergen-induced cutaneous late-phase response. 28 
RECENT ADVANCES IN AIT FOR FOOD ALLERGY AND ATOPIC DERMATITIS
An increasing prevalence of food allergy in children and the observation that it takes longer than previously thought to outgrow food allergies 44 increases the need for novel treatments for food allergies other than avoidance, which remains the standard of care. 45 Different routes of AIT have been investigated, including OIT, epicutaneous immunotherapy (EPIT), SLIT, and SCIT approaches. The recent publications of RCTs are summarized in Table II . [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] It is important to recognize the great heterogeneity of the trials in food allergy. 49 Dosing schemes, treatment duration, and primary outcomes vary highly between trials, and included numbers of patients are rather small. Nevertheless, there is increasing evidence that desensitization to food allergens with AIT might be effective at least for the protection against accidental exposure.
45 Two dose-finding RCTs have studied the efficacy of peanut EPIT by using an allergen patch delivery system 50, 51 and revealed a modest but significant treatment effect compared with placebo after 52 weeks of treatment. The treatment was found to be safe and well tolerated. Peanut EPIT is currently being assessed in a phase III trial.
A trial in young children aged 9 to 36 months at randomization specifically aimed to evaluate the safety, efficacy, and feasibility of early peanut OITwith 2 doses. 52 In both treatment arms, a high proportion of children reached sustained unresponsiveness 4 weeks after treatment discontinuation. OIT treatment in preschool children had a favorable safety profile. 52 Peanut OIT later in life showed a higher efficacy for treatment of peanut allergy compared with SLIT, but higher frequencies of adverse reactions have been reported as a disadvantage. 47 The combination of food AIT with omalizumab might further increase tolerability and efficacy and reduce the time needed for updosing, as shown for cow's milk and peanut allergy. 53, 54 The use of hydrolyzed preparations for egg allergy might be another approach to increase safety 55 ; larger RCTs will be needed to further assess these novel treatments.
To date, there is no consistent evidence supporting the effectiveness of AIT for the treatment of atopic dermatitis. Despite the demand for high-quality research to further evaluate the role of AIT in atopic dermatitis, [56] [57] [58] no new RCTs have been published recently.
ADVERSE EVENTS AND SAFETY
A European survey on systemic adverse reactions (SARs) aimed to monitor the real-life situation by asking physicians in 3 countries, 94% of whom were allergists, about adverse events in patients undergoing AIT for pollen, Alternaria species, and animal dander. 59 A total of 4316 patients, more than 50% with asthma comorbidity with a follow-up of 15 months, were studied. Forty-eight percent were polysensitized, and 17% had at least 1 AIT before current treatment for another allergen. About half of the products were native allergens, and the other half were allergoids; subcutaneous applications were preferred in Germany and Spain, and the sublingual route was preferred in France (mainly drops). About half of the patients received conventional updosing schemes, and the others received either cluster or rush schemes. Of the patients, 2.1% experienced at least 1 systemic reaction, and 88% of the SARs were observed in patients receiving SCIT (>57,000 applications) and 11% in patients receiving SLIT (>259,000 applications). Acute urticaria (26 cases) and dyspnea (17 cases) were only seen in patients receiving SCIT, and AR symptoms were seen in 21 patients receiving SCIT and 2 patients receiving SLIT. Seventy-six percent of the SARs occurred during SCIT updosing. Only 4 SARs were considered severe (0.07% of patients or 0.00007% of injections).
A higher risk of systemic reactions in patients receiving SCITwas associated with natural allergens versus allergoids and pollen and animal dander versus mites, in patients with systemic reactions in the history, and when cluster schemes were applied. Asthma tended to also increase the risk but remained insignificant. The favorable adverse event records for SLITare confirmed by a pooled analysis of observations with a 5-grass tablet showing no SARs; the most frequent treatment-emergent AEs were local-site oropharyngeal reactions consistent with the sublingual route of administration.
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A 10-year prospective study on the safety of AIT, which was initiated after a cluster of severe reactions (grade 3-5 reactions according to European and World Allergy Organization classifications) and introduction of a slower updosing protocol in Denmark in 2003, monitored more than 102,000 injections and found a rate of 4 severe reactions per 100,000 injections. 61 According to these authors, the rate of severe reactions should not be higher than 0.004% of the injections. Safety requirements for performing procedures in allergy offices, including optimal safety measures (eg, supervision, availability of safety equipment, and access to specialized emergency services), have been recommended. 62 
MECHANISMS OF AIT Role of mast cells and basophils in AIT
Mast cells and basophils have 2 types of effect on mechanisms of action of AIT, which can be classified as very early desensitization effects and late responses in tissues. Very early events are mainly based on changes in thresholds of rapid degranulation of mast cells and basophils, and late effects are based on decreased tissue infiltration and a decrease in their mediators. Both early and late effects have been shown to change during AIT, and several key articles have been published in the area. Decreased activation of mast cells and basophils can happen within a few hours in patients undergoing ultrarush venom immunotherapy; however, it takes 3 to 4 months during OIT. 63, 64 Thus far, there were several mechanisms proposed, such as the role of histamine receptor 2 and IgG binding to FcgRIIb. [65] [66] [67] [68] Several studies have been published during the last years to help us better understand the role of basophils in AIT. In a recent study, MacGlashan and Hamilton 69 showed that CD32 affects FcεRI activity inhibition in human basophils. The function of CD32 to inhibit activation of FcεRI in human basophils suggests that measurements of IgG 2 and IgG 3 antibodies are warranted in immunotherapy studies. IgG 2 and IgG 3 appear to be the most efficacious in recruiting CD32 into interactions with antigens and antibodies on the human basophil.
One recent study indicates that human basophils might not directly respond to and be modulated by dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin (DC-SIGN) and mannose receptor-binding nonoxidized mannan-coupled allergoids because they do not express DC-SIGN and mannose receptors, unlike dendritic cells (DCs). In addition, the data suggest that if DC-SIGN and mannose receptor-binding allergens are not IgE bound, they cannot activate human basophils. Accordingly, the expression pattern of DC-SIGN and mannose receptors on effector cells contributes to the diversity of allergic and tolerogenic responses. 70 Biomarkers related to mechanisms of AIT and personalized medicine AIT represents the most widely used and historically the earliest and most efficient personalized medicine approach. Personalized/ precision medicine approaches and novel biomarkers have been extensively investigated during the past years. [71] [72] [73] Recent studies found several biomarkers in basophils and mast cells that can be used to determine the efficacy of the immunotherapy response. The basophil diamine oxidase molecule was proposed in one of the recent studies. In the SCIT, SLIT, and sublingual immunotherapy-participated 3 years (SLIT-TOL) groups percentages of allergen-stimulated diamine oxidase-positive chemoattractant receptor-homologous molecule expressed on T H 2 lymphocytes (CRTH2) 1 basophils were found to be greater compared with those in patients with seasonal AR. Similarly, there were lower proportions of CRTH2 1 basophils expressing surface CD203c bright , CD63, and CD107a. Histamine release from basophils and serum inhibitory activity for IgE-FAB in all immunotherapy groups were found to be significantly greater compared with those from the seasonal AR group. 74 Abundance and activity of effector cells also change in response to peanut immunotherapy. In the long-term follow-up of a randomized multicenter trial using SLIT for peanut allergy, 2-year responders to AIT had significantly lower percentages of CD63 1 basophils than nonresponders. 75 In a recent study a fish allergy mouse model mimicking IgE epitope recognition and symptoms of human disease was developed. Mice and rabbits were immunized with a hypoallergenic Cyp c 1 mutant that inhibited IgE binding to Cyp c 1. It was concluded that the blocking IgG antibodies generated against hypoallergenic Cyp c 1 can protect against fish allergy.
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In another study on peanut allergy, basophils and mast cells sensitized with plasma from patients with peanut allergy but not peanut-sensitized patients showed dose-dependent activation in response to peanut. Depletion of IgG 4 from plasma of peanut allergic (and undergoing peanut OIT) children sensitized to Ara h 1 or Ara h 3 partially restored peanut-induced mast cell activation. 77 Analysis with quantitative proteomics of pretreatment sera from patients with grass pollen allergy revealed a strong decrease in rhinoconjunctivitis symptoms after sublingual immunotherapy, which was observed in patients with high levels of O-glycosylated sialylated Fetuin-A isoforms. In addition to this, a significant upregulation of airway hyperresponsiveness, lung resistance, and T H 2 responses after allergic sensitization to ovalbumin (OVA) was observed after in vivo silencing of the FETUA gene in BALB/c mice. 78 
New findings on the role of DCs in AIT
Documenting the changes occurring in DCs during AIT is important because the efficiency of allergen-specific T-cell responses in immunotherapy directly correlates with the capability of AIT for skewing DCs. A study observed that 5 molecular markers predominantly expressed by blood DCs (ie, C1Q and CD141) or shared with lymphoid cells (ie, FcgRIIIA, GATA3, and RIPK4) reflect changes to regulatory/proallergic responses in peripheral blood. These markers can be used to monitor the early inception of AIT efficacy as early as 2 months after the start of AIT. 79 Induction of regulatory T (Treg) cells by tolerizing DC subsets is an important aspect of immune tolerance induction during AIT. Accordingly, it was observed that IL-27 secreted from mature retinoic acid-skewed DCs was important for inducing CD25 ) retinoic acid-skewed DCs was ineffective in inducing tolerance to food allergens. It is suggested in this study that induction of Foxp3 2 Treg cells through regulatory DCs inducing immunotherapy or use of regulatory DCs themselves might be a useful strategy for tolerance against food allergies (Fig 1) . 80 Additionally, a recent study has identified oral CD103 
CD11b
1 cDCs transport sublingual antigens to draining submandibular lymph node and induce antigen-specific Foxp3
1 Treg cells, a viable strategy for developing cDC-based therapeutic approaches in SLIT. 81 
Role of T cells in AIT

Suppression of effector T cells and induction of Treg cells have been one of the hallmarks of the mechanisms of AIT
J ALLERGY CLIN IMMUNOL VOLUME 140, NUMBER 5 (Fig 2) . 82, 83 T-cell receptor (TCR) sequencing of allergen-specific T-cell clones during and after immunotherapy will mark new developments for the characterization of T cells in AIT in the near future.
A study based on next-generation sequencing of peanutproliferative TCRb in subjects undergoing OIT has found that the peanut allergen-induced proliferation assay leads to a polyclonal response that is extremely diverse, although consistent clones make up only a small fraction of the T-cell response. Peanut OIT changes the distribution of this consistent fraction of allergen-specific T cells, supporting the T-cell replacement hypothesis as a mechanism of food OIT. 84 In a cohort of participants with peanut allergy, it was observed that allergen-specific CD4 1 T cells expand and shift toward an ''anergic'' T H 2 T-cell phenotype with successful immunotherapy, a phenomenon that is not present in either pretreatment participants or healthy control subjects. 85 Some recent studies have focused on the immunoregulatory effects of SCIT and intradermal immunotherapy and their effects on the generation of Treg cells. Production of OVA-specific IgE was decreased, but IgG 2a production was increased after epicutaneous immunization with OVA and CpG. Moreover, IL-4, IL-5, IL-10, and IL-13 responses and peroxidase activity of eosinophils are suppressed. Reduction of IgE synthesis is dependent on 86 Another study on food allergy showed that epicutaneous application of antigen generated a population of gastrointestinal homing LAP 1
Foxp3
2 Treg cells. Mast cells were suppressed by Treg cells with the TGFb-dependent pathway in the absence of modulation for Tand B-cell responses. These data highlight immune communication between the skin and gastrointestinal tract and identify novel mechanisms through which epicutaneous tolerance can suppress food-induced anaphylaxis. 87 A study investigating the efficacy of intradermal AIT was not clinically effective and resulted in worsening of respiratory allergic symptoms. However, the study was able to show suppressed late-phase skin responses. Intradermal immunotherapy increased serum Phleum pratense-specific IgE levels compared with those in the control arm. T cells expanded from arm biopsy specimens of subjects undergoing intradermal immunotherapy had higher T H 2 surface marker CRTH2 expression and lower expression of the T H 1 marker CXCR3, respectively. Interestingly, skin late-phase responses remained inhibited 7 months after treatment. 22 
Innate lymphoid cells and immune regulation
Innate lymphoid cells are arising as the new players that induce allergic inflammation in addition to T H 2 cells. 88 They are in close interaction and cross-talk with T H 2 cells for T H 2 cytokine and IgE production. 89 Type 2 innate lymphoid cells (ILC2s) are dominant in allergic patients in the circulation, and affected tissues might play a role in continuation of the allergic status and resistance to AIT. 90 IL-33-stimulated ILC2s block the generation of allergen-specific Treg cells and favor food allergy through production of IL-4 in mice. These findings suggest that blocking the IL-33/IL-33 receptor pathway or suppressing general ILC2 activation represents an innovative approach for the treatment of food allergy. 91 Circulation and presence of ILC2s in the peripheral blood system and affected tissues of allergic patients might have a role in continuation of the allergic status and resistance to AIT. 90 
Recent reports on B-cell regulation in AIT
During the last few years, it appeared that B-cell regulation is equally important as T-cell regulation in AIT. Human regulatory B (Breg) cells, particularly their IL-10 production, were demonstrated to increase during AIT. 92, 93 Peanut OIT induces an early and transient expansion of circulating Ara h 2-specific memory B cells that peaks at week 7. By using a novel affinity selection approach to identify antigen-specific B cells, a recent study demonstrated that the early peanut OIT-induced Ara h 2-specific B-cell receptor repertoire is oligoclonal and somatically hypermutated and shares similar clonal groups among unrelated subjects consistent with convergent selection. 94 Supporting this concept, liposomes simultaneously targeting CD22 and the B-cell receptor specific for the major peanut allergen Ara h 2 can be used to prevent sensitization to Ara h 2. Based on previous studies with other antigens, it can be hypothesized that simultaneous engagement of CD22 and the Ara h 2-specific B-cell receptor leads to deletion of Ara h 2-specific B cells. These findings provide the foundation for the development of a novel therapy for peanut allergy using a highly targeted, antigen-specific approach. 95 In addition to these, most peanut allergenspecific B cells express mutated and class-switched antibodies. After immunotherapy, multiple B-cell clones that recognize narrow allergen epitopes increase in frequency. OIT was also shown to increase the somatic mutation rate of allergen-specific IgG 4 . 96 However, in another study peanut-specific binding patterns were very similar for IgE and IgG 4 . This might indicate that the IgE and IgG 4 antibodies are clonally related. 97 Use of viral vectors might also be a viable strategy for inducing suppressive responses from B cells. A recent study revealed that treatment with innocuous parainfluenza virus vector rhPIV2/IL-10 through a nasal approach improves pollinosis symptoms without affecting the systemic immune response, plasma IgE and T H 2 cytokine levels, and cytokine profiles of distant lymphoid organs. The data suggest that intranasal rhPIV2/ IL-10 can be used as a novel therapeutic tool for nasal allergy. 98 Recent studies have added new biomarkers for detecting and targeting Breg cells for controlling allergic inflammation. Selb et al 99 showed that casein-and food-induced allergic responses in mice can be controlled by IL-10-producing CD5
1 Breg cells. The population of IL-10-producing CD5
1 B cells showed an increase in mesenteric lymph nodes but not in spleens or the peritoneal cavity in OT mice. Casein-induced allergic responses were suppressed by adoptive transfer of CD5 1 B cells from mesenteric lymph nodes in an allergen-specific and IL-10-dependent manner. CD5
1 B cells from the spleen and peritoneal cavity did not induce the same effect. This inhibitory effect was shown to be dependent on Foxp3 1 Treg cells. Through Foxp3 1 Treg cells, the mesenteric IL-10-producing Breg cells control food allergy, and mesenteric Breg cells can potentially act as a therapeutic regulator for food allergy. 100 Furthermore, CD23 surface density 
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Suppressive and tolerogenic B-cell frequencies are greater after bee venom immunotherapy and in patients with occupations with regular allergen exposure, such as beekeepers. In the study by Boonpiyathad et al, 101 allergic patients and beekeepers showed increased frequencies of plasmablasts, phospholipase A (PLA)-specific memory B cells, and IL-10-secreting CD73 2 CD25
1 CD71 1 B R 1 cells. After exposure to bee venom, PLA-specific IgG 4 -switched memory B cells were observed to expand. PLA-specific B cells also showed increased expression of CCR5 after high-dose allergen exposure, whereas CXCR4, CXCR5, CCR6, an CCR7 expression was unaffected. 101 New findings on regulation of allergen-specific IgE and IgG 4 antibodies and the blocking antibody effect of IgG 4 The efficacy of sublingual tablets in patients undergoing OIT has been investigated by several studies. Adults with HDM-induced AR with or without conjunctivitis and asthma received 12 developmental units (DU) of HDM sublingual immunotherapy tablet MK-8237 (Merck/ALK-Abell o, Hørsholm, Denmark), 6 DU of MK-8237, or placebo daily for 24 weeks. MK-8237 with a dose of 12 DU reduced nasal and ocular symptoms. Specific IgE and IgG 4 levels increased with the 12-and 6-DU treatments versus placebo at week 8, and significant increments with IgE and IgG 4 levels were observed at week 24. 12 In another study adults with HDM-associated AR were given a daily placebo tablet or sublingual immunotherapy tablet (STG320) for 6 months. At study entry, serum levels of Dermatophagoides pteronyssinus-and Dermatophagoides farinae-specific IgE and IgG 4 were similar across treatment groups. Within the first 2 treatment months, mite allergen-specific serum IgE levels increased 5-to 7-fold in the active treatment group and then gradually decreased while remaining unchanged in the placebo group. Mite allergen-specific serum IgG 4 levels increased over the treatment period in the active treatment group and showed a small change in the placebo group. 13 Two studies that monitored IgG 4 responses during birch pollen immunotherapy have reported that Bet v 1-specific IgG 4 repertoires induced by birch pollen extract AIT do not broadly expand in the course of treatment in most of the patients. IgG 4 diversity increased in 20% of patients with prolonged therapy. 102 A second study applied a chimera-based approach to monitor development of the Bet v 1-specific IgE, IgG 1 , and IgG 4 repertoires during 3 years of AIT in subjects. In most patients treated with allergen chimera peptides, Bet v 1-specific IgE levels increased during the early phase of treatment, followed by a gradual decrease. All patients had Bet v 1-specific IgG 4 , and 64% of patients had Bet v 1-specific IgG 1 . In these subjects Bet v 1-specific IgG 4 levels increased later than IgG 1 levels. The data suggest that allergen-specific IgE and AIT-induced IgG 4 and IgG 1 repertoires differ between each other but did not expand over time. Both IgG 1 and IgG 4 induced during AIT displayed more restricted epitope diversities than IgE antibodies. 103 Furthermore, Bet v 1-derived molecules containing COPs were shown to lead to a significant increase in serum Bet v 1-specific IgG 4 levels in all but a few patients. Specific IgG 4 levels were significantly increased compared with placebo in both treated groups after treatment, as well as during and after the pollen season. 26 Studies monitoring the efficacy of egg OIT concluded sustained unresponsiveness (a clinical remission with immunologic effects) of the immune system to the allergen persists after cessation of long-term egg OIT. Children with egg allergy received egg OIT for up to 4 years or placebo for 1 year or less. Over time, egg-specific IgG 4 levels were significantly greater in the sustained unresponsiveness group. Similarly, scores of egg-specific skin prick tests were observed to be significantly lower in those achieving sustained unresponsiveness. For egg IgE levels and basophil activation, there was a decrease over time in those achieving sustained unresponsiveness; however, the differences were not significant. 104 For introduction of egg early in life, a recent study found that the IgG 4 response to egg proteins and IgG 4 /IgE ratios were found to be higher in children introduced to egg protein at 12 months. Introduction of whole egg powder into the diets of high-risk infants reduced sensitization to egg white and induced egg-specific IgG 4 . However, 8.5% of infants exposed to egg protein were not susceptible to this primary prevention. 105 In addition, increased levels of egg white-specific IgA and IgA 2 were found biomarkers for clinical response to egg OIT. 106 In another study food allergy-prone IL-4raF709 mice treated with specific IgG at the beginning of feeding showed prevention of IgE antibody, T H 2 response, and anaphylaxis development on challenge. When given as a supplement to oral desensitization in mice with established IgE-mediated hypersensitivity, IgG antibodies facilitated re-establishment of tolerance, probably because of favoring the expansion of Foxp3
1 Treg cells along with suppression of existing IgE and T H 2 responses. Adaptive allergic responses were suppressed with IgG and FcgRIIb through their effect on mast cell function. 67 Predominant Api m 10 sensitization was shown to be a risk factor for treatment failure in patients undergoing honeybee venom (HBV) immunotherapy. In patients with HBV allergy who underwent controlled honeybee sting challenge after at least 6 months of bee venom immunotherapy, no differences were observed between responders and nonresponders regarding levels of IgE sensitization to Api m 1, 2, 3, and 5. In contrast, Api m 10-specific IgE levels were moderately but significantly increased in nonresponders. Specific IgG 4 induction to Api m 10 was observed only in patients unresponsive to bee venom immunotherapy. Results from allergic patients suggest that predominant IgE sensitization to Api m 10 might be an increased risk factor for treatment failure in patients undergoing HBV immunotherapy. 107 Several recent studies were directed toward investigating changes in allergen-specific IgE and IgG 4 responses during peanut immunotherapy and how different methods of immunotherapy affect IgE and IgG 4 levels during and after peanut immunotherapy. Peanut-specific IgE levels are significantly less in children treated with early OIT, and those children are 19 times more likely to be able to consume peanut compared with matched control subjects. Allergic side effects during early OIT were common, but all were mild to moderate. 52 Uotila et al 108 reported that specific IgE to Ara h 2 and 6 decreased significantly during OIT. Although baseline measurements showed low amounts of specific IgG 4 to Ara h 1, 2, 3, 6, 8, and 9 and whole peanut extract, specific IgG 4 levels to these allergens significantly increased during OIT. OIT resulted in increased IgG 4 /IgE ratios for Ara h 1, 2, 3, and 6 and whole peanut extract, whereas those for Ara h 8 and 9 remained stable. The strongest correlations were observed for Ara h 2, 3, and 6 and whole peanut extract. The study concluded that serologic response to peanut allergens during OIT is directed toward 2S albumins and peanut storage proteins.
Burk et al 109 also reported that in patients undergoing peanut SLIT, lower levels of Ara h 2-and Ara h 3-specific IgE, as well as peanut, are among the markers of successful desensitization. Another study confirmed these findings by showing increases in peanut-specific IgG 4 levels and IgG 4 /IgE ratios in peanut EPIT-treated participants, along with trends toward reduced basophil activation and peanut-specific T H 2 cytokine levels. 51 The Epidemiologic Study on the Genetics and Environment of Asthma, Bronchial Hyperresponsiveness, and Atopy investigated the effects of route of exposure to allergens by analyzing IgE and IgG responses to 47 inhaled and food allergens collected from 5 French regions. The study showed that the variability of allergen-specific IgE and IgG frequencies depends on the dose and route of exposure and overall immunogenicity of the allergen. Allergen contact through the oral route might preferentially induce IgG responses. 110 A multicenter birth cohort study testing IgG and IgG 4 responses against 91 allergenic molecules reported that the route of allergen exposure and initial status of IgE sensitization were profoundly important to the children's repertoire to foodborne and airborne allergens at 2 years of age, whereas the amount of IgG 4 isotype was only marginally involved. These IgG responses are more frequent and stronger in children with current IgE sensitization. 111 
Novel vaccine approaches and their mechanisms
Adjuvanticity of certain allergen modifications and novel adjuvants represent an important part of novel vaccine approaches, and related innate mechanisms might define efficacy in patients receiving AIT. 112 New findings for increasing efficacy for allergoid immunotherapy show that low-dose therapy with a chemically modified monomeric allergoid of Der p 2 alone was not fully successful, but supplementation of vitamin D 3 was associated with limited changes in the immunologic parameters in the lung. In contrast, the most prominent decrease in airway eosinophilia and T H 2 cytokine levels and the concomitant increase in Treg cell counts, IL-10 levels in the lung, and Der p 2-specific IgG 2a levels in serum were induced by allergoid vaccine adjuvanted with vitamin D 3 .
113
Characterization and peptide sequencing of major allergen types and exploitation of their structure for recombinant peptide-based AIT might be a viable strategy for increasing the efficacy of AIT. A 19-mer peptide sequence in the immunodominant region of Can f 4 was identified as a potential target for the development of peptide-based AIT together with the observation that productive T H 2-deviated memory T-cell responses to Can f 4 are observed in allergic but not nonallergic subjects. 114 Allergen peptide carrier vaccines are being developed in line with the same concept. A novel grass pollen peptide carrier vaccine, BM32, has been shown to have a lower effect on lymphocyte proliferation compared with grass pollen extract, and BM32 also induced significantly lower secretion of proinflammatory cytokines. 115 Another study with the modified Bet v 1 allergen MBC4 used directed epitope rearrangements combined with a knowledge-based structural modification. The new recombinant allergen was unable to bind IgE from allergic patients. Still, properties to activate specific T cells or induce blocking antibodies were conserved. MBC4 was suggested to be a viable vaccine candidate for treatment of birchand Bet v 1-cross-reactive and food allergies simultaneously. 116 A major development in this regard is the mannan-coated allergoids for use as allergen vaccines. Human DCs can capture glutaraldehyde-polymerized allergoids conjugated to nonoxidized mannan, which display in vivo hypoallergenicity, much more efficiently than native grass pollen P pratense allergens or mannan-free glutaraldehyde-polymerized allergoids. Uptake of mannan-conjugated allergoids depends on mannose receptor and DC-SIGN-mediated internalization. Nonoxidized mannan allergoid skews human DCs to generate functional Foxp3 1 Treg cells through programmed death ligand 1. Immunization of mice with nonoxidized mannan induces a shift to nonallergic responses and increases the frequency of splenic Foxp3
1 Treg cells (Fig 3) . 83, 117 New studies on conjugated allergoids show efficacy in control of inflammation in patients with various allergic diseases. A recent study showed that numbers of eosinophils in bronchoalveolar lavage fluid and lung tissue, total IgE levels, and production of IL-13 from lung mononuclear cells all decreased significantly in the BALB/c mice challenged and treated with Toll-like receptor 7 ligand-allergen conjugates in comparison with nDer p 2-treated mice. nDer p 2-conjugated stimulated spleen cells showed a significant increase in IFN-g and IL-10 levels, as well as IgG 2a levels. Similar effects were elicited by treatment with OVA conjugate in an OVA-driven BALB/c model. Cytofluorometric analysis demonstrated that the conjugate expanded IFN-g-and IL-10-producing memory T cells. IL-10 2/2 and IL-12 2/2 mice were used to confirm the role of IL-10 and IFN-g in inducing a protective and balanced redirection the T H 2-mediated airway inflammation. 118 In another study milk-sensitized mice undergoing specific EPIT prevented further sensitization to peanut or HDM. Humoral responses, airway hyperresponsiveness, eosinophilic esophageal infiltration, and T H 2 cytokine levels were all reduced with EPIT and sustained for more than 2 months. Moreover, the adoptive transfer of Treg cells from mice undergoing EPIT completely prevented sensitization to peanut and peanut-induced anaphylaxis. Milk EPIT also enhanced methylation of the GATA-3 promoter region. 119 Targeting the complement system might become a new strategy for increasing the efficacy of AIT and inhibiting allergic inflammation. Recently, the complement subunit C1q was identified as a marker for monocyte-derived regulatory DCs, supporting the differentiation of IL-10-secreting CD4
1 T cells with suppressive activity. Furthermore, C1q expression is upregulated in PBMCs of allergic patients in the course of successful AIT. Expression or secretion of molecules, such as C1q, can confer a potent direct anti-inflammatory function to regulatory DCs independent of their capacity for expanding the pool of Treg cells. 120 
AIT combined with biological agents and probiotics
Studies on the combination of biological agents with AIT seemed more and more frequent in recent years. A combined therapy comprising a probiotic together with peanut OIT was recently reported. Cotreatment of the probiotic Lactobacillus rhamnosus CGMCC 1.3724 and peanut OIT in children with peanut allergy was associated with reduced peanut skin prick test responses and peanut-specific IgE levels and increased peanut-specific IgG 4 levels. This is the first RCT assessing the novel coadministration of a probiotic and peanut OIT and evaluating sustained unresponsiveness in children with peanut allergy. 46 Similarly, for milk immunotherapy, combining omalizumab therapy with milk OIT led to distinct alterations in basophil reactivity but not T-cell responses. 121 According to the same concept, a multicenter RCT study has shown that long-term use of omalizumab has benefits for long-term efficacy. Subjects continuing omalizumab had significantly better asthma control. Discontinuation of omalizumab was associated with an increase in free IgE levels and an increase in basophil expression of the high-affinity IgE receptor. 122 Another study investigating the effects of omalizumab treatment in conjunction with OIT for milk allergy found that casein-specific IgE levels were significantly increased in the omalizumab-treated group at the 4th month and then reduced at the 32nd month. In the omalizumab-treated group percentages of CD63 1 basophils were found to be lower compared with those in the placebo group at the 28th month. Afterward, at the 32nd month, the percentage of CD63
1 basophils in the omalizumab-treated group reached levels similar to those in the placebo group. 53 Short-term grass pollen SCIT under the umbrella of anti-IL-4 was investigated in a recent study. Treatment with anti-IL-4 and SCIT compared with SCIT alone induced decreased allergenspecific IL-4-producing cell counts. Dual IL-4/IL-10-producing cells were induced in both active treatment arms during the pollen season. There was no additional benefit of the combination of anti-IL-4 with SCIT over SCIT alone. 43 
CONCLUSION
Recent developments in the clinics and cellular and molecular mechanisms of AIT aim at enhancing clinical and immunologic tolerance, decreasing side effects, and increasing efficacy. Several clinical trials have been completed successfully during the last couple of years, reaching an end point. Hypoallergenic recombinant allergen and allergoid vaccines and use of probiotics, vitamins, and biologic agents as supplements to support AIT are expected to enhance efficacy. Many novel developments in molecular mechanisms that affect early desensitization, T-and B-cell tolerance, specific antibody regulation, and induction of IgG 4 and several key molecules that can act as biomarkers are continuously being developed (see Table E2 in this article's Online Repository at www. jacionline.org). As new technologies and novel strategies emerge, we are in need of more research into the mechanisms, biomarker discovery, and disease phenotyping for AIT. AIT represents the most common and one of the very few human in vivo relevant antigen-specific immune tolerance models, and there will always be take-home messages for other immune tolerance-related conditions, such as autoimmunity, organ transplantation, chronic infections, cancer, and recurrent abortions.
